Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Mabs|December 18, 2014
Failure to upregulate cell surface PD-1 is associated with dysregulated stimulation of T cells by TGN1412-like CD28 superagonistThilipan Thaventhiran, Naif Alhumeed, Han X A Yeang, et al.
International Journal of Toxicology|May 23, 2022
Comprehensive Nonclinical Safety Assessment of Nirmatrelvir Supporting Timely Development of the SARS-COV-2 Antiviral Therapeutic, Paxlovid™Jean G Sathish, Siddhartha Bhatt, Jamie K DaSilva, et al.
Nature Reviews. Drug Discovery|March 29, 2013
Challenges and approaches for the development of safer immunomodulatory biologicsJean G Sathish, Swaminathan Sethu, Marie-Christine Bielsky, et al.
Open Forum Infectious Diseases|August 10, 2023
Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Intravenous Infusions of PF-07304814 (Lufotrelvir) in Participants Hospitalized With COVID-19Philip Robinson, Sima S Toussi, Sudeepta Aggarwal, et al.
Science (New York, N.Y.)|November 2, 2021
An oral SARS-CoV-2 M<sup>pro</sup> inhibitor clinical candidate for the treatment of COVID-19Dafydd R Owen, Charlotte M N Allerton, Annaliesa S Anderson, et al.
Biorxiv : the Preprint Server for Biology|September 16, 2020
Discovery of a Novel Inhibitor of Coronavirus 3CL Protease for the Potential Treatment of COVID-19Britton Boras, Rhys M Jones, Brandon J Anson, et al.
Nature Communications|October 19, 2021
Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19Britton Boras, Rhys M Jones, Brandon J Anson, et al.
Journal of Medicinal Chemistry|April 30, 2024
A Second-Generation Oral SARS-CoV-2 Main Protease Inhibitor Clinical Candidate for the Treatment of COVID-19Charlotte M N Allerton, Joel T Arcari, Lisa M Aschenbrenner, et al.
Journal of Medicinal Chemistry|February 28, 2025
Discovery of Nirmatrelvir (PF-07321332): A Potent, Orally Active Inhibitor of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2) Main ProteaseJamison B Tuttle, Christophe Allais, Charlotte M N Allerton, et al.
Pageof 2